Heteronemin and Tetrac Induce Anti-Proliferation by Blocking EGFR-Mediated Signaling in Colorectal Cancer Cells

Heteronemin and Tetrac Induce Anti-Proliferation by Blocking EGFR-Mediated Signaling in Colorectal Cancer Cells

Overexpressed EGFR and mutant <i>K-Ras</i> play vital roles in therapeutic resistance in colorectal cancer patients. To search for an effective therapeutic protocol is an urgent task. A secondary metabolite in the sponge <i>Hippospongia</i> sp., Heteronemin, has been shown to...

Full description

Bibliographic Details
Main Authors:	Sukanya Unson, Tung-Cheng Chang, Yung-Ning Yang, Shwu-Huey Wang, Chi-Hung Huang, Dana R. Crawford, Haw-Ming Huang, Zi-Lin Li, Hung-Yun Lin, Jacqueline Whang-Peng, Kuan Wang, Paul J. Davis, Wen-Shan Li
Format:	Article
Language:	English
Published:	MDPI AG 2022-07-01
Series:	Marine Drugs
Subjects:	heteronemin tetrac colorectal cancer <i>KRAS</i> EGFR signaling
Online Access:	https://www.mdpi.com/1660-3397/20/8/482

Similar Items

Combined Treatment of Heteronemin and Tetrac Induces Antiproliferation in Oral Cancer Cells
by: Chi-Hung Huang, et al.
Published: (2020-07-01)

Heteronemin Induces Anti-Proliferation in Cholangiocarcinoma Cells via Inhibiting TGF-β Pathway
by: Hung-Yun Lin, et al.
Published: (2018-12-01)

In Vivo Clearance of Apoptotic Debris From Tumor Xenografts Exposed to Chemically Modified Tetrac: Is There a Role for Thyroid Hormone Analogues in Efferocytosis?
by: Kavitha Godugu, et al.
Published: (2022-03-01)

Breaking down Leukemia Walls: Heteronemin, a Sesterterpene Derivative, Induces Apoptosis in Leukemia Molt4 Cells through Oxidative Stress, Mitochondrial Dysfunction and Induction of Talin Expression
by: Yu-Cheng Chen, et al.
Published: (2018-06-01)

Corrigendum: Tetrac and NDAT Induce Anti-proliferation via Integrin αvβ3 in Colorectal Cancers With Different K-RAS Status
by: Yu-Tang Chin, et al.
Published: (2019-04-01)

Heteronemin Suppresses Lymphangiogenesis Through ARF-1 and MMP-9/VE-Cadherin/Vimentin
by: Hsien-Lin Chen, et al.
Published: (2021-08-01)

"Corrigendum: Cancer cell gene expression modulated from plasma membrane integrin alphavbeta3 by thyroid hormone and nanoparticulate tetrac"
by: Paul eDavis
Published: (2015-06-01)

Heteronemin, a Marine Sesterterpenoid-Type Metabolite, Induces Apoptosis in Prostate LNcap Cells via Oxidative and ER Stress Combined with the Inhibition of Topoisomerase II and Hsp90
by: Man-Gang Lee, et al.
Published: (2018-06-01)

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition.
by: Alessandro eOttaiano, et al.
Published: (2013-01-01)

Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
by: Shen Shanxiang, et al.
Published: (2012-05-01)

A Case of Non-Small Cell Lung Cancer with Mutually Exclusive <i>EGFR</i> and <i>KRAS</i> Mutations
by: Abhimanyu Tushir, et al.
Published: (2025-01-01)

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
by: Didik Setyo Heriyanto, et al.
Published: (2022-12-01)

Differential Expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues
by: Liang Hong, et al.
Published: (2012-04-01)

Association between EGFR, ALK and KRAS Gene Status and Synchronous Distant  Organ Metastasis in Non-small Cell Lung Cancer
by: Ge GAO, et al.
Published: (2018-07-01)

An Explainable Radiogenomic Framework to Predict Mutational Status of KRAS and EGFR in Lung Adenocarcinoma Patients
by: Berardino Prencipe, et al.
Published: (2023-06-01)

Response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status
by: Oscar Arrieta, et al.
Published: (2020-04-01)

Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways
by: Li Gong, et al.
Published: (2024-12-01)

Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma
by: Masaoki Ito, et al.
Published: (2023-03-01)

Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review
by: Juhi Mody, et al.
Published: (2024-03-01)

MOLECULAR MARKERS OF SENSITIVITY AND RESISTANCE OF COLORECTAL CANCER TO ANTI-EGFR T
by: A. O. Ivantsov, et al.
Published: (2016-04-01)

<i>KRAS</i> and <i>BRAF</i> Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
by: Nuria Garcia-Carbonero, et al.
Published: (2020-01-01)

Dynamic Evaluation of Circulating miRNA Profile in <i>EGFR</i>-Mutated NSCLC Patients Treated with EGFR-TKIs
by: Alessandro Leonetti, et al.
Published: (2021-06-01)

Identification of Antimycobacterial Natural Products from a Library of Marine Invertebrate Extracts
by: Kojo Sekyi Acquah, et al.
Published: (2022-01-01)

A pulmonary enteric adenocarcinoma patient harboring a rare EGFR exon 19 P753S mutation: Case report and review
by: Xiaohu Xu, et al.
Published: (2022-09-01)

Erlotinib Treatment in Colorectal Cancer Suppresses Autophagy Based on <i>KRAS</i> Mutation
by: Alexander Siegman, et al.
Published: (2024-07-01)

Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment
by: Juliana F. Vilachã, et al.
Published: (2020-08-01)

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients
by: Carlos E. Bacchi, et al.
Published: (2012-01-01)

Reliability of <it>KRAS</it> mutation testing in metastatic colorectal cancer patients across five laboratories
by: Feigelson Heather, et al.
Published: (2012-04-01)

A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors
by: Thomas McFall, et al.
Published: (2020-03-01)

Overcoming EGFR Resistance in Metastatic Colorectal Cancer Using Vitamin C: A Review
by: Ahmad Machmouchi, et al.
Published: (2023-02-01)

Improved Biological Impacts of Anti-EGFR Monoclonal Antibody in KRAS-Mutant Colorectal Cancer Cells by Silica-Coated Magnetic Nanoparticle Conjugation
by: Maedeh Yousefi, et al.
Published: (2024-10-01)

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an <i>EGFR</i>-Activating Mutation
by: Shigetoshi Nishihara, et al.
Published: (2022-07-01)

Association between <i>EGFR</i> Gene Mutation and Antioxidant Gene Polymorphism of Non-Small-Cell Lung Cancer
by: Ching-Hsiung Lin, et al.
Published: (2020-09-01)

Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy
by: Lin JIANG, et al.
Published: (2022-07-01)

Eicosapentaenoic Acid Inhibits <i>KRAS</i> Mutant Pancreatic Cancer Cell Growth by Suppressing Hepassocin Expression and STAT3 Phosphorylation
by: Ching-Feng Chiu, et al.
Published: (2021-03-01)

Concordance of Abundance for Mutational <i>EGFR</i> and Co-Mutational <i>TP53</i> with Efficacy of <i>EGFR</i>-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung Cancer
by: Youping Wang, et al.
Published: (2023-09-01)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?
by: Hyun Ae Jung, et al.
Published: (2020-10-01)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
by: Ming-Hung Huang, PhD, et al.
Published: (2022-11-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
by: Nathaniel J. Myall, MD, et al.
Published: (2025-02-01)

Limited Efficacy of Anti-EGFR Monoclonal Antibodies in Colorectal Cancer Patients with Rare RAS Variants: Analysis of the C-CAT Database
by: Shuhei Suzuki, et al.
Published: (2024-12-01)